ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,706.29
-0.96%
S&P 500
5,219.80
-0.30%
Dow Jones
38,155.00
0.11%
US Dollar vs Yen
156.646
-0.20%
Brent Oil
81.685
-0.32%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. AMEX
  6. Matinas Biopharma Holdings Inc (MTNB)

  7. Matinas Biopharma Holdings Inc (MTNB) ニュース

MTNB

Matinas Biopharma (MTNB)

Matinas Biopharma Holdings Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:AMEX:MTNB
日付受信時刻ニュースソース見出しコード企業名
2024/05/1620 : 00GlobeNewswire Inc.New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024AMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/1005 : 06Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/1005 : 05GlobeNewswire Inc.Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/1005 : 01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/0721 : 00GlobeNewswire Inc.Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingAMEX:MTNBMatinas Biopharma Holdings Inc
2024/05/0220 : 00GlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024AMEX:MTNBMatinas Biopharma Holdings Inc
2024/04/3021 : 00GlobeNewswire Inc.In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyAMEX:MTNBMatinas Biopharma Holdings Inc
2024/04/0321 : 30GlobeNewswire Inc.Matinas BioPharma Prices $10 Million Registered Direct OfferingAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2805 : 05GlobeNewswire Inc.Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2521 : 00GlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2222 : 15GlobeNewswire Inc.Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseAMEX:MTNBMatinas Biopharma Holdings Inc
2024/03/2219 : 30GlobeNewswire Inc.Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2622 : 05Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2622 : 00GlobeNewswire Inc.Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2021 : 35Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/02/2021 : 30GlobeNewswire Inc.Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisAMEX:MTNBMatinas Biopharma Holdings Inc
2024/01/0921 : 30Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2024/01/0321 : 00GlobeNewswire Inc.Matinas BioPharma to Present at Biotech Showcase 2024AMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2721 : 40Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2721 : 30GlobeNewswire Inc.Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2121 : 40Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/2121 : 30GlobeNewswire Inc.Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
2023/12/1611 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
 Showing the most relevant articles for your search:AMEX:MTNB

最近閲覧した銘柄

USOTC
AGRTF
Applied Graphite Technol... (QB)
BIT
F21697
Vontobel Financial Produ...
BIT
P1M6R8
BNP Paribas Issuance
USOTC
GXSBF
Geox Spa Biadene di Mont... (PK)
EU
ACAQU
Crdit Agricole 4000% unt...
TG
ERD6
BlackRock Global Funds
BIT
P1UFO9
NLBNPIT1UFO9 20351221 81...
NASDAQ
IMCV
iShares Morningstar Mid ...
COIN
FINALEUSD
Bens Finale
BIT
P10IW9
Bnp Paribas Issuance
BIT
F37248
Vontobel Financial Produ...
BIT
P1R9M8
BNP Paribas Issuance
TG
BR00
Cruz Battery Metals
TG
LN00
Cult Food Science
BOV
BDVD39
Global X Funds
BIT
F15695
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有